Only 14 pages are availabe for public view
Epilepsy is a chronic disorder of the brain that affects people of all ages. Approximately 50 million people live with epilepsy worldwide. Epilepsy exists when someone has an epileptic seizures.
Focal seizures also initially generate in and affect just one part of the brain or a whole hemisphere. Symptoms vary according to where the seizure occurs particularly at onset, are determined by localization and not etiology.
Drug-resistant epilepsy is defined as failure of adequate trials of two tolerated, appropriately chosen and administered antiepileptic drugs (whether as monotherapy or in combination) to achieve sustained seizure freedom. And, about 20 to 40 percent of patients with epilepsy are refractory to medications.
A core feature of drug-resistant epilepsy is hyperexcitability of the cortical areas. These syndromes may benefit from rTMS.
Neurostimulation based treatments for epilepsy are an alternative for the many patients who remain refractory to standard antiepileptic drugs.
Our study was a prospective comparative study conducted on 30 patients with drug resistant focal epilepsy and divided into two groups; active and sham rTMS treatment groups to assess the effectiveness of rTMS as adjunctive treatment. based on our results and previous studies, we conclude that the use of rTMS in selected refractory cases of epilepsy can be useful has a potential clinical use in drug -resistant patients with epilepsy of neocortical origin in whom anatomical information can be used to guide rTMS coil placement, if low-frequency rTMS is applied at relatively high intensities over repeated sessions.